These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 19596059)

  • 21. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.
    Kassem MA; Abdel Rahman AA; Ghorab MM; Ahmed MB; Khalil RM
    Int J Pharm; 2007 Aug; 340(1-2):126-33. PubMed ID: 17600645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanosuspensions of a poorly soluble investigational molecule ODM-106: Impact of milling bead diameter and stabilizer concentration.
    Singhal M; Baumgartner A; Turunen E; van Veen B; Hirvonen J; Peltonen L
    Int J Pharm; 2020 Sep; 587():119636. PubMed ID: 32659405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Development of Silymarin nanocrystals lyophilized power applying nanosuspension technology].
    Zhao X; Wang G; Zhang B; Li H; Nie Q; Zang C; Zhao X
    Zhongguo Zhong Yao Za Zhi; 2009 Jun; 34(12):1503-8. PubMed ID: 19777833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Freeze-dried nifedipine-lipid nanoparticles with long-term nano-dispersion stability after reconstitution.
    Ohshima H; Miyagishima A; Kurita T; Makino Y; Iwao Y; Sonobe T; Itai S
    Int J Pharm; 2009 Jul; 377(1-2):180-4. PubMed ID: 19446623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is the combination of cellulosic polymers and anionic surfactants a good strategy for ensuring physical stability of BCS Class II drug nanosuspensions?
    Bilgili E; Li M; Afolabi A
    Pharm Dev Technol; 2016; 21(4):499-510. PubMed ID: 25774989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Formation of nanosuspensions in bottom-up approach: theories and optimization.
    Ahmadi Tehrani A; Omranpoor MM; Vatanara A; Seyedabadi M; Ramezani V
    Daru; 2019 Jun; 27(1):451-473. PubMed ID: 30661188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Process parameter dependent growth phenomena of naproxen nanosuspension manufactured by wet media milling.
    Bitterlich A; Laabs C; Krautstrunk I; Dengler M; Juhnke M; Grandeury A; Bunjes H; Kwade A
    Eur J Pharm Biopharm; 2015 May; 92():171-9. PubMed ID: 25766272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ibuprofen-loaded nanoparticles prepared by a co-precipitation method and their release properties.
    Jiang B; Hu L; Gao C; Shen J
    Int J Pharm; 2005 Nov; 304(1-2):220-30. PubMed ID: 16182477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanosuspensions as advanced printing ink for accurate dosing of poorly soluble drugs in personalized medicines.
    Pardeike J; Strohmeier DM; Schrödl N; Voura C; Gruber M; Khinast JG; Zimmer A
    Int J Pharm; 2011 Nov; 420(1):93-100. PubMed ID: 21889582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physical stability of nanosuspensions: investigation of the role of stabilizers on Ostwald ripening.
    Verma S; Kumar S; Gokhale R; Burgess DJ
    Int J Pharm; 2011 Mar; 406(1-2):145-52. PubMed ID: 21185926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of the Interaction between Diclofenac and Ibuprofen with Benzalkonium Chloride to Prepare Ocular Nanosuspension.
    Tak D; Rimpy ; Kumar T; Ahuja M
    Recent Pat Drug Deliv Formul; 2019; 13(4):301-309. PubMed ID: 31849291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving flow properties of ibuprofen by fluidized bed particle thin-coating.
    Ehlers H; Räikkönen H; Antikainen O; Heinämäki J; Yliruusi J
    Int J Pharm; 2009 Feb; 368(1-2):165-70. PubMed ID: 19010403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the amorphous fraction of a dried nanosuspension caused by milling or by drying? A case study with Naproxen and Cinnarizine.
    Kayaert P; Van den Mooter G
    Eur J Pharm Biopharm; 2012 Aug; 81(3):650-6. PubMed ID: 22579733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of arginine hydrochloride and hydroxypropyl cellulose as stabilizers on the physical stability of high drug loading nanosuspensions of a poorly soluble compound.
    Ain-Ai A; Gupta PK
    Int J Pharm; 2008 Mar; 351(1-2):282-8. PubMed ID: 18036751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is roller milling - the low energy wet bead media milling - a reproducible and robust milling method for formulation investigation of aqueous suspensions?
    Zulbeari N; Holm R
    Int J Pharm; 2024 Feb; 651():123733. PubMed ID: 38142873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development.
    Sigfridsson K; Lundqvist AJ; Strimfors M
    Drug Dev Ind Pharm; 2009 Dec; 35(12):1479-86. PubMed ID: 19929207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour.
    Lai F; Sinico C; Ennas G; Marongiu F; Marongiu G; Fadda AM
    Int J Pharm; 2009 May; 373(1-2):124-32. PubMed ID: 19429297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanocrystals: comparison of the size reduction effectiveness of a novel combinative method with conventional top-down approaches.
    Salazar J; Ghanem A; Müller RH; Möschwitzer JP
    Eur J Pharm Biopharm; 2012 May; 81(1):82-90. PubMed ID: 22233547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Solution calorimetry as an alternative approach for dissolution testing of nanosuspensions.
    Kayaert P; Li B; Jimidar I; Rombaut P; Ahssini F; Van den Mooter G
    Eur J Pharm Biopharm; 2010 Nov; 76(3):507-13. PubMed ID: 20887787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanosizing drug particles in supercritical fluid processing.
    Pathak P; Meziani MJ; Desai T; Sun YP
    J Am Chem Soc; 2004 Sep; 126(35):10842-3. PubMed ID: 15339159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.